Law360, New York (April 25, 2006, 12:00 AM EDT) -- In a boost for Ranbaxy Laboratories Ltd., an Austrian court has upheld an earlier decision invalidating Pfizer Inc.'s patent on Lipitor, enabling the Indian generic drug maker to push forward in its attempt to launch a generic version of the blockbuster cholesterol drug.
The five-judge panel of the Supreme Patent and Trademark Board of Austria unanimously affirmed an earlier ruling delivered in March 2005, Ranbaxy revealed on Tuesday.
The decision marks a key departure from the recent verdicts handed down in the Lipitor saga in various...
Austrian Court Hands Ranbaxy Lipitor Win
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
